ArticleBritish journal of cancer2026
Genomic and transcriptomic landscape of spread through air spaces in stage 1 lung adenocarcinoma.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
introductionSpread through air spaces (STAS) is an adverse histologic feature in early-stage lung adenocarcinoma (LUAD) incorporated into the ninth edition TNM staging. Despite its clinical significance, the molecular features underlying STAS in stage 1 LUAD remain incompletely characterised.
methodsPatients with stage 1 LUAD and known STAS status were identified. Whole exome and RNA sequencing were performed on tumour samples with matched normal controls. Disease-free survival (DFS) was analysed using the Kaplan-Meier method and Cox regression.
resultsAmong 378 patients, 54.2% had STAS+ tumours, with similar incidence between EGFR-mutant and EGFR-wildtype LUAD. STAS+ tumours were significantly associated with stage 1B disease, lymphovascular invasion, higher histological grade, micropapillary or solid predominant adenocarcinoma subtype and PD-L1 tumour proportion score ≥1%. STAS+ remained independently associated with inferior DFS after multivariable adjustment (hazard ratio 2.32, 95% CI 1.16-4.63; p = 0.017). At the molecular level, STAS+ tumours were enriched for TP53 co-mutations, whole genome doubling, non-TRU transcriptomic subtypes and upregulation of cell cycle-related pathways, with directionally consistent findings across EGFR-mutant and EGFR-wildtype tumours.
conclusionsSTAS+ in stage 1 LUAD is associated with a distinct molecular phenotype characterised by genomic instability and cell cycle dysregulation, consistent with a more aggressive biological phenotype with implications for risk stratification and adjuvant therapy selection.
Identifiers
42760303What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.